BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 8932871)

  • 1. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support.
    Franklin WA; Shpall EJ; Archer P; Johnston CS; Garza-Williams S; Hami L; Bitter MA; Bast RC; Jones RB
    Breast Cancer Res Treat; 1996; 41(1):1-13. PubMed ID: 8932871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and transplantation of highly purified autologous peripheral CD34+progenitor cells: purging efficacy, hematopoietic reconstitution following high dose chemotherapy in patients with breast cancer: results of a feasibility study in Japan.
    Chou T; Sano M; Ogura M; Morishima Y; Itagaki H; Tokuda Y
    Breast Cancer; 2005; 12(3):178-88. PubMed ID: 16110287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
    Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
    Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity.
    Maletz K; Kufer P; Mack M; Raum T; Pantel K; Riethmüller G; Gruber R
    Int J Cancer; 2001 Aug; 93(3):409-16. PubMed ID: 11433407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cells.
    Burgess J; Mills B; Griffith M; Mansour V; Weaver CH; Schwartzberg LS; Snyder EL; Krause DS; Yanovich S; Prilutskaya M; Umiel T; Moss TJ
    Cytotherapy; 2001; 3(4):285-94. PubMed ID: 12171717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer.
    Preti RA; Lazarus HM; Winter J; Stadtmauer EA; Nadasi S; McMannis J; Karandish S; Jennis A; Goldberg SL; Pecora AL
    Cytotherapy; 2001; 3(2):85-95. PubMed ID: 12028831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined positive/negative purging and transplantation of peripheral blood progenitor cell autografts in breast cancer patients: a pilot study.
    Mapara MY; Körner IJ; Lentzsch S; Krahl D; Reichardt P; Dörken B
    Exp Hematol; 1999 Jan; 27(1):169-75. PubMed ID: 9923456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment.
    Shpall EJ; Jones RB; Bearman SI; Franklin WA; Archer PG; Curiel T; Bitter M; Claman HN; Stemmer SM; Purdy M
    J Clin Oncol; 1994 Jan; 12(1):28-36. PubMed ID: 7505806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of immunomagnetic selection in purging autologous peripheral blood progenitor cell of breast cancer patients].
    Han X; Shi Y; Zhang W
    Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):203-6. PubMed ID: 11953162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
    Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
    J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer.
    Ross AA; Miller GW; Moss TJ; Kahn DG; Warner NE; Sweet DL; Louie KG; Schneidermann E; Pecora AL; Meagher RC
    Bone Marrow Transplant; 1995 Jun; 15(6):929-33. PubMed ID: 7581093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous bone marrow support and bone disease in metastatic breast cancer.
    Nabholtz JM; al-Tweigeri T; Jacquelin N; Venner PM
    Can J Oncol; 1995 Dec; 5 Suppl 1():33-9. PubMed ID: 8853522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer.
    Cooper BW; Moss TJ; Ross AA; Ybanez J; Lazarus HM
    J Clin Oncol; 1998 Nov; 16(11):3509-17. PubMed ID: 9817268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
    Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
    Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CD34+ cells: biological aspects].
    Benedetti F
    Tumori; 1996; 82(2 Suppl):S3-13. PubMed ID: 8928236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests.
    Davies FE; Rawstron AC; Pratt G; Coupe R; Clarke D; Lubenko A; Short K; Perren TJ; Selby PJ; Maclennan S; Major K; Woodhead V; Robinson F; Child JA; Smith GM; Johnson PW; Morgan GJ
    Hematol Oncol; 2000 Sep; 18(3):111-20. PubMed ID: 11027980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of high-dose chemotherapy and monoclonal antibody in breast-cancer patients: a pilot trial to monitor treatment effects on disseminated tumor cells.
    Hempel P; Müller P; Oruzio D; Behr W; Brockmeyer C; Wochner M; Ehnle S; Riethmüller R; Schlimok G
    Cytotherapy; 2000; 2(4):287-95. PubMed ID: 12042038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
    Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction.
    Mapara MY; Körner IJ; Hildebrandt M; Bargou R; Krahl D; Reichardt P; Dörken B
    Blood; 1997 Jan; 89(1):337-44. PubMed ID: 8978310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.